TY - JOUR
T1 - The impact of oat (Avena sativa) consumption on biomarkers of renal function in patients with chronic kidney disease
T2 - A parallel randomized clinical trial
AU - Rouhani, Mohammad Hossein
AU - Mortazavi Najafabadi, Mojgan
AU - Surkan, Pamela J.
AU - Esmaillzadeh, Ahmad
AU - Feizi, Awat
AU - Azadbakht, Leila
N1 - Funding Information:
The authors are grateful for the financial support provided by the Research Council of the Food Security Research Center ( 394192 ), Isfahan University of Medical Sciences, Isfahan, Iran ( 394192 ).
Publisher Copyright:
© 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism
PY - 2018/2
Y1 - 2018/2
N2 - Background & objective: Animal studies report that oat (Avena sativa L) intake has favorable effects on kidney function. However, the effects of oat consumption have not been assessed in humans. The aim of this study was to examine the impact of oat intake on biomarkers of renal function in patients with chronic kidney disease (CKD). Methods: Fifty-two patients with CKD were randomly assigned to a control group (recommended to reduce intake of dietary protein, phosphorus, sodium and potassium) or an oat consumption group (given nutritional recommendations for controls +50 g/day oats). Blood urea nitrogen (BUN), serum creatinine (SCr), urine creatinine, serum albumin, serum potassium, parathyroid hormone (PTH), serum klotho and urine protein concentration were measured at baseline and after an eight-week intervention. Creatinine clearance was calculated using urine creatinine concentration. Results: Within group analysis showed a significant increase in BUN (P = 0.02) and serum potassium (P = 0.01) and a marginally significant increment in SCr (P = 0.08) among controls. However, changes in the oat group were not significant. In a multivariate adjusted model, we observed a significant difference in change of serum potassium (−0.03 mEq/L for oat group and 0.13 mEq/L for control group; P = 0.01) and a marginally significant difference in change of serum albumin (0.01 g/dl for oat group and −0.08 for control group; P = 0.08) between the two groups. There was no change in PTH concentration. Conclusion: Intake of oats may have a beneficial effect on serum albumin and serum potassium in patients with CKD. Registration code: Present study registered under IRCT.ir identifier no. IRCT2015050414551N2.
AB - Background & objective: Animal studies report that oat (Avena sativa L) intake has favorable effects on kidney function. However, the effects of oat consumption have not been assessed in humans. The aim of this study was to examine the impact of oat intake on biomarkers of renal function in patients with chronic kidney disease (CKD). Methods: Fifty-two patients with CKD were randomly assigned to a control group (recommended to reduce intake of dietary protein, phosphorus, sodium and potassium) or an oat consumption group (given nutritional recommendations for controls +50 g/day oats). Blood urea nitrogen (BUN), serum creatinine (SCr), urine creatinine, serum albumin, serum potassium, parathyroid hormone (PTH), serum klotho and urine protein concentration were measured at baseline and after an eight-week intervention. Creatinine clearance was calculated using urine creatinine concentration. Results: Within group analysis showed a significant increase in BUN (P = 0.02) and serum potassium (P = 0.01) and a marginally significant increment in SCr (P = 0.08) among controls. However, changes in the oat group were not significant. In a multivariate adjusted model, we observed a significant difference in change of serum potassium (−0.03 mEq/L for oat group and 0.13 mEq/L for control group; P = 0.01) and a marginally significant difference in change of serum albumin (0.01 g/dl for oat group and −0.08 for control group; P = 0.08) between the two groups. There was no change in PTH concentration. Conclusion: Intake of oats may have a beneficial effect on serum albumin and serum potassium in patients with CKD. Registration code: Present study registered under IRCT.ir identifier no. IRCT2015050414551N2.
KW - Avena sativa
KW - Chronic kidney disease
KW - Oats
KW - Randomized clinical trial
UR - http://www.scopus.com/inward/record.url?scp=85008600062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008600062&partnerID=8YFLogxK
U2 - 10.1016/j.clnu.2016.11.022
DO - 10.1016/j.clnu.2016.11.022
M3 - Article
C2 - 28003041
AN - SCOPUS:85008600062
SN - 0261-5614
VL - 37
SP - 78
EP - 84
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 1
ER -